VRTX

Vertex Pharmaceuticals Incorporated Common Stock (VRTX) | Rumor.io

Vertex Pharmaceuticals

VRTX

Attention (50-day avg)0%

Attention rank (50-day avg)#833

Bullish sentiment (50-day avg)81%

Price to earnings ratio30.7

Market capitalization133.7B

Earnings per share17.1

Dividend yield (TTM)—

Revenue (annual)12B

Net income (annual)4B

Social

What share of all stock conversation is about VRTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% +0	0% 0	0% -0.02

Sep 22

Vertex Pharmaceuticals announces positive results from Phase 2b AMPLIFIED study of Inaxaplin in additional populations with APOL1-mediated kidney disease.
Analyst Truist calls Vertex's Phase 2b inaxaplin data a validation of APOL1 inhibition in AMKD and sees a 100,000+ extra patient opportunity, plus positive readthrough for Maze.
Vertex's kidney disease prospect Inaxaplin has demonstrated potential "best-in-class" data in mid-stage trials, opening up a larger kidney disease opportunity.

Generated by AI

Sentiment

Of the messages about VRTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	95.24% -4.76	75.77% -10.51	89.31% +9.59
Bearish	—	4.76% +4.76	24.23% +10.51	10.69% -9.59

Bullish· Jul 7

Vertex Pharmaceuticals' acquisition of Crinetics Pharmaceuticals for $10 billion is expected to be accretive to adjusted operating income.
The deal expands Vertex's presence in the endocrine disease treatment category, a new therapeutic area for the company.
The acquisition is seen as a strategic move that could drive significant revenue growth, with potential targets exceeding $5 billion annually.

Bearish· Aug 5

$VRTX's Q2 financial results were down 20% and several investment firms lowered their price targets on the stock.
The company's Vx-993 Phase 2 trial failed to meet its primary endpoint, leading to a significant drop in the stock price.
The stock's decline is also attributed to the company's broader pipeline being discounted by the market, with the current market capitalization starting to reflect the failure of VX-993.

Generated by AI

Topics

Of the messages about VRTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	95.45%	39.37%	61.66%
Technical Analysis	—	4.55%	0.63%	12.06%
Analysts	—	0%	32.7%	8.02%
Earnings	—	0%	13.65%	16%
Macro	—	0%	13.65%	0.74%
Controversies	—	0%	0%	1.52%

Earnings· Nov 3

Vertex Pharmaceuticals ($VRTX) reported Q3 2025 earnings with adjusted EPS of $4.80, beating estimates by $0.22.
Revenue for Q3 2025 was $3.08B, a 11.0% year-over-year increase and in-line with estimates.
The company guided FY25 revenue to $11.9B-$12.0B, in-line with estimates, and adjusted R&D and SG&A expenses to $5.65-$5.8B and $5.0-$5.1B, respectively.

Analysts· May 2

Vertex Pharmaceuticals $VRTX price target raised to $380.00 by HC Wainwright, to $384.00 by Barclays, to $410.00 by Oppenheimer, to $340.00 by Stifel Nicolaus, and to $315.00 by RBC Capital.
Analysts at Oppenheimer maintain an Outperform rating and raise price target to $410.00, while those at Stifel Nicolaus raise price target to $340.00.
Truist Securities analyst Robyn Karnauskas maintains a Buy rating and raises price target from $341 to $456.00, while RBC Capital analyst Brian Abrahams maintains a Sector Perform rating and raises price target from $299 to $315.00.

Announcements· Jul 29

Vertex Pharmaceuticals ($VRTX) has partnered with AbCellera ($ABCL) to develop multispecific T-cell engagers for autoimmune diseases and other conditions, with an upfront payment of $28 million.
The collaboration will see Vertex fund all research and development costs, with AbCellera eligible to receive preclinical, development, regulatory, and commercial milestone payments, as well as tiered royalties on net sales.
This partnership marks Vertex's latest autoimmune TCE play, following its growth as a giant in cystic fibrosis medicines, and highlights the company's focus on multiple growth engines, including gene-editing.

Technical Analysis· Oct 15

$VRTX has potential for a 10pt bounce from its current level, with the 1min 200ma serving as a target.
The stock is breaking down into the close, forming a lower high setup after retracing losses, and may test its march lows.
$VRTX has a potential short entry after a RT, with a similar setup on the 1min chart, and the 150 day SMA on the 1D candle chart is telling.

Generated by AI

Community

Of the messages about VRTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	61.82%	69.22%	53.82%
Newcomers	—	38.18%	30.78%	46.18%

Regulars· Aug 10

Vertex Pharmaceuticals' stock surged 5.61% to $523.91 after competitor Sionna Therapeutics halted development of a cystic fibrosis treatment following disappointing Phase 2a results.
Sionna's trial flop removes a key threat to Vertex, which is now poised to maintain its market lead in cystic fibrosis treatments.
Vertex's pipeline is expected to drive future growth, with Pove (povetacicept) approval potentially happening sooner than most think, and the company being well-positioned to address various indications including IgA Nephropathy, Lupus Nephritis, and Generalized Myasthenia Gravis.

Newcomers· Aug 10

$VRTX stock jumps 7% after Sionna Therapeutics' cystic fibrosis drug fails trial, removing a potential competitive threat.
Vertex Pharmaceuticals reports Q2 revenue of $3.33B (+12% YoY), raises FY guidance to $13.1-13.2B, and receives price target lifts from Barclays and Truist.
The recent success of $VRTX stock is attributed to the company's dominance in the cystic fibrosis market, with a major threat evaporating after Sionna Therapeutics' drug fails its Phase 2 trial.

Generated by AI

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 6.27% on an annualized basis producing an average annual return of 19.81%. Currently, Vertex Pharmaceuticals has a market

16h agoBenzinga

Vertex Pharmaceuticals- Still Too Much Emphasis On CF Supremacy - I Foresee A Downgrade

23h agoSeeking Alpha

2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right. | The Motley Fool

This biotech player is firing on all cylinders.

1d agoThe Motley Fool

Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?

On September 22, Truist analyst Danielle Brill identified a “significant positive readthrough” for Maze Therapeutics, Inc. (NASDAQ:MAZE) following positive Phase 2 topline data from Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The data validates APOL1 inhibition in classic APOL1-mediated kidney disease (AMKD), supporting an addressable population of over 100,000 patients. Truist reiterated a Buy rating and $64 target […]

1d agoYahoo Finance

2 Healthcare Stocks That Just Delivered Great News for Investors | The Motley Fool

And there could be more positive developments ahead.

3d agoThe Motley Fool

Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know

Vertex Pharmaceuticals (VRTX) closed at $522.38 in the latest trading session, marking a +1.17% move from the prior day.

5d agoYahoo Finance

Also Discussed

Investors talking about VRTX also mention

#	Name	Attention
1	CRISPR Therapeutics AGCRSP	0%0
2	Regeneron Pharmaceuticals, Inc.REGN	0%-0.01
3	Alnylam Pharmaceuticals, Inc.ALNY	0%0
4	Biogen IncBIIB	0%-0.01
5	BioMarin Pharmaceutical IncBMRN	0%+0
6	Incyte Corp.INCY	0%new
7	Editas Medicine, Inc.EDIT	0%+0
8	Intellia Therapeutics, Inc.NTLA	0%+0
9	Amgen Inc.AMGN	0.01%+0
10	Agios Pharmaceuticals, Inc.AGIO	0%0

Vertex Pharmaceuticals Incorporated Common Stock

Healthcare
Biotechnology

Vertex Pharmaceuticals Incorporated Common Stock represents ownership in Vertex Pharmaceuticals Incorporated, a global biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious diseases. The company’s current portfolio is centered on cystic fibrosis therapies and has expanded into additional specialty disease areas through products such as CASGEVY and JOURNAVX. Vertex serves patients across the United States, Europe, and other international markets, with a business model that combines specialized research, regulatory development, manufacturing, and commercialization capabilities. The company is known for operating in highly scientific and tightly regulated therapeutic markets, where innovation, clinical expertise, and product execution are central to its role. Vertex Pharmaceuticals Incorporated Common Stock is used by investors to track and participate in the performance of a biotechnology business with a strong presence in specialty pharmaceuticals and advanced medicine development.

Website

Location

50 Northern Avenue

Boston, MA, 02210

United States

Social

What share of all stock conversation is about VRTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% +0	0% 0	0% -0.02

Sep 22

Vertex Pharmaceuticals announces positive results from Phase 2b AMPLIFIED study of Inaxaplin in additional populations with APOL1-mediated kidney disease.
Analyst Truist calls Vertex's Phase 2b inaxaplin data a validation of APOL1 inhibition in AMKD and sees a 100,000+ extra patient opportunity, plus positive readthrough for Maze.
Vertex's kidney disease prospect Inaxaplin has demonstrated potential "best-in-class" data in mid-stage trials, opening up a larger kidney disease opportunity.

Generated by AI

Sentiment

Of the messages about VRTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	95.24% -4.76	75.77% -10.51	89.31% +9.59
Bearish	—	4.76% +4.76	24.23% +10.51	10.69% -9.59

Bullish· Jul 7

Vertex Pharmaceuticals' acquisition of Crinetics Pharmaceuticals for $10 billion is expected to be accretive to adjusted operating income.
The deal expands Vertex's presence in the endocrine disease treatment category, a new therapeutic area for the company.
The acquisition is seen as a strategic move that could drive significant revenue growth, with potential targets exceeding $5 billion annually.

Bearish· Aug 5

$VRTX's Q2 financial results were down 20% and several investment firms lowered their price targets on the stock.
The company's Vx-993 Phase 2 trial failed to meet its primary endpoint, leading to a significant drop in the stock price.
The stock's decline is also attributed to the company's broader pipeline being discounted by the market, with the current market capitalization starting to reflect the failure of VX-993.

Generated by AI

Topics

Of the messages about VRTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	95.45%	39.37%	61.66%
Technical Analysis	—	4.55%	0.63%	12.06%
Analysts	—	0%	32.7%	8.02%
Earnings	—	0%	13.65%	16%
Macro	—	0%	13.65%	0.74%
Controversies	—	0%	0%	1.52%

Earnings· Nov 3

Vertex Pharmaceuticals ($VRTX) reported Q3 2025 earnings with adjusted EPS of $4.80, beating estimates by $0.22.
Revenue for Q3 2025 was $3.08B, a 11.0% year-over-year increase and in-line with estimates.
The company guided FY25 revenue to $11.9B-$12.0B, in-line with estimates, and adjusted R&D and SG&A expenses to $5.65-$5.8B and $5.0-$5.1B, respectively.

Analysts· May 2

Vertex Pharmaceuticals $VRTX price target raised to $380.00 by HC Wainwright, to $384.00 by Barclays, to $410.00 by Oppenheimer, to $340.00 by Stifel Nicolaus, and to $315.00 by RBC Capital.
Analysts at Oppenheimer maintain an Outperform rating and raise price target to $410.00, while those at Stifel Nicolaus raise price target to $340.00.
Truist Securities analyst Robyn Karnauskas maintains a Buy rating and raises price target from $341 to $456.00, while RBC Capital analyst Brian Abrahams maintains a Sector Perform rating and raises price target from $299 to $315.00.

Announcements· Jul 29

Vertex Pharmaceuticals ($VRTX) has partnered with AbCellera ($ABCL) to develop multispecific T-cell engagers for autoimmune diseases and other conditions, with an upfront payment of $28 million.
The collaboration will see Vertex fund all research and development costs, with AbCellera eligible to receive preclinical, development, regulatory, and commercial milestone payments, as well as tiered royalties on net sales.
This partnership marks Vertex's latest autoimmune TCE play, following its growth as a giant in cystic fibrosis medicines, and highlights the company's focus on multiple growth engines, including gene-editing.

Technical Analysis· Oct 15

$VRTX has potential for a 10pt bounce from its current level, with the 1min 200ma serving as a target.
The stock is breaking down into the close, forming a lower high setup after retracing losses, and may test its march lows.
$VRTX has a potential short entry after a RT, with a similar setup on the 1min chart, and the 150 day SMA on the 1D candle chart is telling.

Generated by AI

Community

Of the messages about VRTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	61.82%	69.22%	53.82%
Newcomers	—	38.18%	30.78%	46.18%

Regulars· Aug 10

Vertex Pharmaceuticals' stock surged 5.61% to $523.91 after competitor Sionna Therapeutics halted development of a cystic fibrosis treatment following disappointing Phase 2a results.
Sionna's trial flop removes a key threat to Vertex, which is now poised to maintain its market lead in cystic fibrosis treatments.
Vertex's pipeline is expected to drive future growth, with Pove (povetacicept) approval potentially happening sooner than most think, and the company being well-positioned to address various indications including IgA Nephropathy, Lupus Nephritis, and Generalized Myasthenia Gravis.

Newcomers· Aug 10

$VRTX stock jumps 7% after Sionna Therapeutics' cystic fibrosis drug fails trial, removing a potential competitive threat.
Vertex Pharmaceuticals reports Q2 revenue of $3.33B (+12% YoY), raises FY guidance to $13.1-13.2B, and receives price target lifts from Barclays and Truist.
The recent success of $VRTX stock is attributed to the company's dominance in the cystic fibrosis market, with a major threat evaporating after Sionna Therapeutics' drug fails its Phase 2 trial.

Generated by AI

Vertex Pharmaceuticals

Social

Sep 22

Bullish· Jul 7

Bearish· Aug 5

Earnings· Nov 3

Analysts· May 2

Announcements· Jul 29

Technical Analysis· Oct 15

Regulars· Aug 10

Newcomers· Aug 10

$100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today - Vertex Pharmaceutic

Vertex Pharmaceuticals- Still Too Much Emphasis On CF Supremacy - I Foresee A Downgrade

2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right. | The Motley Fool

Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?

2 Healthcare Stocks That Just Delivered Great News for Investors | The Motley Fool

Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know

Also Discussed

Vertex Pharmaceuticals Incorporated Common Stock

Company Information

Location

$100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today - Vertex Pharmaceutic

Vertex Pharmaceuticals- Still Too Much Emphasis On CF Supremacy - I Foresee A Downgrade

2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right. | The Motley Fool

Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?

2 Healthcare Stocks That Just Delivered Great News for Investors | The Motley Fool

Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know

Also Discussed

Social

Sep 22

Bullish· Jul 7

Bearish· Aug 5

Earnings· Nov 3

Analysts· May 2

Announcements· Jul 29

Technical Analysis· Oct 15

Regulars· Aug 10

Newcomers· Aug 10